| Literature DB >> 33658811 |
Abstract
BACKGROUND: The objective of our study is to estimate the differences in molecular epidemiology and resistance mechanisms in carbapenem-resistant Acinetobacter baumannii (CRAB) isolates from the ICU and respiratory department(RD) in Fourth Affiliated Hospital of Harbin Medical University.Entities:
Keywords: Acinetobacter baumannii; carbapenem resistance; molecular epidemiology; resistance mechanisms
Year: 2021 PMID: 33658811 PMCID: PMC7920613 DOI: 10.2147/IDR.S299540
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Information Concerning the Primers Used in This Study
| Primer Name | Sequence (5′→3′) | DNA Amplicon Size (bp) | Annealing Temperature (°C) | Reference |
|---|---|---|---|---|
| OXA-23-like | F: GATCGGATTGGAGAACCAGA | 501 | 53.2 | [ |
| OXA-51-like | F:CTAATAATTGATCTACTCAAGTTAC | 988 | 55.1 | [ |
| NDM | F: CGGAATGGCTCATCACGATC | 621 | 50 | [ |
| IMP | F: GGAATAGAGTGGCTTAAYTCTC | 232 | 55 | [ |
| VIM | F: GATGGTGTTTGGTCGCATA | 390 | 55 | [ |
| KPC | F: CGTCTAGTTCTGCTGTCTTG | 798 | 55 | [ |
| F: AGGAGCTAATCATGCGATT | 1259 | 56 | [ | |
| F: GACAACTACAGCTTTACTTGCT | 711 | 57 | [ | |
| SPM | F:AAAATCTGGGTACGCAAACG | 271 | 52 | [ |
| AIM | F:CTGAAGGTGTACGGAAACAC | 322 | 52 | [ |
Abbreviation: CarO, carbapenem-associated resistance OMP.
Summarized Demographic Data for All Patients from Respiratory Department and ICU (n=60)
| Parameter | Quantity Respiratory Department | Quantity ICU | P value |
|---|---|---|---|
| 60.36±15.52 (mean years old ±SD) | 61.48±16.32 (mean years old ±SD) | 0.88 | |
| Male | 60%(18/30) | 63.33%(19/30) | 0.92 |
| Female | 40%(12/30) | 36.67%(11/30) | 0.76 |
| 19.38±13.25 (mean days ±SD) | 21.55±18.87 (mean days ±SD) | 0.62 | |
| 30%(9/30) | 40%(12/30) | 0.59 | |
| 6.67%(2/30) | 23.33%(7/30) | 0.15 | |
| Intubation | 53.33%(16/30) | 70%(21/30) | 0.28 |
| Tracheostomy | 16.67%(5/30) | 30%(9/30) | 0.36 |
| Sputum | 86.67%(26/30) | 76.67%(23/30) | 0.38 |
| Blood | 10%(3/30) | 10%(3/30) | >0.99 |
| Wounds | 3.33%(1/30) | 13.33%(4/30) | 0.35 |
| Urine | 0%(0/30) | 0%(0/30) | |
| 100%(30/30) | 100%(30/30) | >0.99 | |
| 7.9 (2–20) | 9.6 (1–24) | 0.15 | |
| 1.75 (0–7) | 1.11 (0–2) | 0.24 |
Abbreviations: APACHE II, acute physiology and chronic health evaluation II score; SD, standard deviation; ICU, intensive care unit.
Antimicrobial Resistance and Susceptibility Profiles of CRAB Clinical Isolates Obtained from Patients at Respiratory Department and ICU
| Antimicrobial | All Isolates (n=60) | P value* | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC (μg/mL) | Range of Values | Breakpoint (Respiratory) Interpretations | Breakpoint (ICU) Interpretations | ||||||||
| MIC50 | MIC90 | Min | Max | %R | %I | %S | %R | %I | %S | ||
| Piperacillin/Tazobactam | 4 | 64 | ≤1 | >128 | 66.7(20) | 0 | 33.3(10) | 70(21) | 0 | 30(9) | 0.45 |
| Cefoperazone/Sulbactam | 4 | 64 | ≤1 | >128 | 23.3(7) | 10(3) | 66.7(20) | 53.3(16) | 0 | 46.7(14) | 0.03 |
| Imipenem | 0.5 | 8 | ≤0.03 | >32 | 100(30) | 0 | 0 | 100(30) | 0 | 0 | >0.99 |
| Tigecycline | 1 | 2 | ≤0.06 | >16 | 0 | 0 | 100(30) | 23.3(7) | 0 | 76.7(23) | 0.01 |
| Colistin | 1 | 2 | ≤0.06 | >16 | 0 | 0 | 100(30) | 0 | 0 | 100(30) | >0.99 |
| Gentamicin | 2 | 8 | ≤0.5 | >32 | 46.7(14) | 13.3(4) | 40(12) | 60(18) | 10(3) | 30(9) | 0.25 |
| Meropenem | 0.5 | 8 | ≤0.03 | >32 | 100(30) | 0 | 0 | 100(30) | 0 | 0 | >0.99 |
| Amikacin | 4 | 16 | ≤1 | >64 | 43.3(13) | 13.3(4) | 43.4(13) | 53.3(16) | 13.3(4) | 33.7(10) | 0.34 |
| Ceftazidime | 4 | 32 | ≤0.25 | >32 | 53.3(16) | 6.7(2) | 40(12) | 66.7(20) | 10(3) | 23.3(7) | 0.19 |
| Ciprofloxacin | 0.25 | 4 | ≤0.06 | >16 | 53.3(16) | 0 | 46.7(14) | 63.3(19) | 0 | 36.7(11) | 0.15 |
Notes: Breakpoint Interpretation: Amikacin S≤16μg/mL, I=32μg/mL, R≥64μg/mL, Ceftazidime S≤8μg/mL, I=16μg/mL, R≥32μg/mL, Ciprofloxacin S≤1μg/mL, I=2μg/mL, R≥4μg/mL, Colistin S≤2μg/mL, I=4μg/mL, R≥8μg/mL, Gentamicin S≤4μg/mL, I=8μg/mL, R≥16μg/mL, Meropenem S≤2μg/mL, I=4μg/mL, R≥8μg/mL, Piperacillin/Tazobactam S≤16/4μg/mL, I=32/4μg/mL, R≥128/4μg/mL, Cefoperazone/Sulbactam S≤16/4μg/mL, I=32/4μg/mL, R≥128/4μg/mL, Imipenem S≤2μg/mL, I=4μg/mL, R≥8μg/mL, Tigecycline S≤2μg/mL, I=4μg/mL, R≥8μg/mL. * represents result of comparison resistance rate between respiratory department and ICU.
Abbreviations: %S, susceptible; %I, intermediate; %R, %resistant.
PCR Detection of Genes Associated with CRAB Isolates in Respiratory Department and ICU
| Parameter | Respiratory Department(30) % (n) | ICU(30) % (n) | P value |
|---|---|---|---|
| Gene associated with carbapenem resistance | |||
| 56.7 (17) | 80.0 (24) | 0.09 | |
| 0 (0) | 20 (6) | 0.02 | |
| 10 (3) | 40 (12) | 0.02 | |
| 0 (0) | 23.3 (7) | 0.01 | |
| Mutation of CarO | 60 (18) | 86.7 (26) | 0.04 |
| 13.3 (4) | 16.7 (5) | >0.99 |
Abbreviation: carO, carbapenem-associated resistance OMP.
Figure 1Detection of IMP genes of carbapenem-resistant Acinetobacter baumannii clinical isolates by PCR.
Figure 2Detection of VIM genes of carbapenem-resistant Acinetobacter baumannii clinical isolates by PCR.
Figure 3Detection of NDM genes of carbapenem-resistant Acinetobacter baumannii clinical isolates by PCR.
Figure 4Dendrogram displaying the genetic relatedness of 60 CRAB strains, based on pulse field gel electrophoresis results.
The MLST Results of CRAB in Respiratory Department and ICU
| Respiratory Department (n=30) | ICU (n=30) | ||||
|---|---|---|---|---|---|
| Type ST | % (n) | Number | Type ST | % (n) | Number |
| ST92 | 33.3 (10) | 1, 4, 5, 9, 14, 17, 21, 22, 25, 28 | ST92 | 63.3※ (19) | 31, 33,34,35,36,37, 39, 40, 44,45,47,48, 50, 51, 54, 55, 57, 59,60 |
| ST175 | 20.0 (6) | 2,7,11,16,23,27 | ST111 | 20.0 (6) | 12,32,38,46,53,58 |
| ST298 | 13.3 (4) | 8,41,24,26 | ST244 | 10.0 (3) | 13,49,56 |
| ST773 | 6.7 (2) | 42,30 | ST357 | 6.7 (2) | 43,52 |
| ST111 | 6.7 (2) | 3,15 | |||
| ST316 | 6.7 (2) | 18,19 | |||
| ST639 | 3.3 (1) | 6 | |||
| ST991 | 3.3 (1) | 29 | |||
| ST2221 | 3.3 (1) | 10 | |||
| ST1015 | 3.3 (1) | 20 | |||
Note: ※Represents ICU VS respiratory department, P=0.03.